Ulcerative Colitis Market Growth forecast period of 2019-2026
Global Ulcerative Colitis Market is expected to rise gradually to an
estimated value of USD 10.51 billion by
2026, registering a CAGR of 5.4%
in the forecast period of 2019-2026.
This rise in market value can be attributed to the increasing awareness and
concerns regarding the health of patients, large number of pipeline molecule
and government investments.
Ulcerative colitis is a chronic disease that affects the
colon of large intestine. It is characterized by inflammation in the large
intestine, and the symptoms include blood in the stool, diarrhea and abdominal
pain. According to CDC, in 2015, there were approximately 3.0 million people
having IBD (either Crohn’s Disease or ulcerative colitis), other report from
NCBI says that the highest reported prevalence values were in Europe
(ulcerative colitis 505 per 100 000 in Norway) and North America (ulcerative colitis
286 per 100 000 in the USA), almost more than half of these cases could have
been avoided with the availability of proper medical treatment. This
significant number is expected to act as a driver to the market growth.
Get Free
Sample Copy of Report Here: @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-ulcerative-colitis-market
Key Market Competitors: Global Ulcerative Colitis Market
Few of the major competitors currently working in the
ulcerative colitis market are Allergan,
Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Bayer AG, UCB S.A.,
Perrigo Company plc, Pfizer Inc., Johnson & Johnson Services, Inc.,
GlaxoSmithKline plc, Eli Lilly and Co., Sanofi Aventis A/S, AstraZeneca, Merck
& Co., Inc., InDex Pharmaceuticals Holding AB, AJINOMOTO CO.,INC., Abbott,
Circle33, LLC, BioLineRx, CELGENE CORPORATION, Mitsubishi Tanabe Pharma
Corporation, Salix Pharmaceuticals, Inc. and few among others.
Market Drivers
·
Rise
in the incidence and prevalence rate of the disease will drive the growth of
the market
·
Large
number of pipeline molecule will help the market to grow
·
Rise
in the government and non-government investment in the R&D
Market Restraints
·
Strict
government regulations Is restraining the market growth
·
Patent
expiry of blockbuster drugs will result in generic and biosimilar competition
·
Lower
incidence rate in Asia- pacific regions restricts the growth of market in that
particular area
Table of Content:
Part 01: Executive Summary
Part 02: Scope of The Report
Part 03: Global Ulcerative Colitis Market Landscape
Part 04: Global Ulcerative Colitis Market Sizing
Part 05: Global Ulcerative Colitis Market
Segmentation by Product
Part 06: Five Forces Analysis
Part 07: Customer Landscape
Part 08: Geographic Landscape
Part 09: Decision Framework
Part 10: Drivers and Challenges
Part 11: Market Trends
Part 12: Vendor Landscape
Part 13: Vendor Analysis
Segmentation: Global Ulcerative Colitis Market
·
By Type
o
Ulcerative
Proctitis
o
Proctosigmoiditis
o
Left-Sided
Colitis
o
Pancolitis
or Universal Colitis
o
Fulminant
Colitis
·
By Drug Type
o
Anti-Inflammatory
Drugs
o
Aminosalicylates
o
Corticosteroids
o
Anti-TNF
biologics
o
Immunosuppressant
o
Calcineurin
Inhibitors
o
Other
Drug Types
·
By Molecule Type
o
Small
Molecules
o
Biologics
·
By End- User
o
Hospital
Pharmacies
o
Retail
Pharmacies
o
Drug
Store
o
E-commerce
·
By Route of Administration
o
Parentral
o
Oral
By Geography
·
Asia Pacific
o
China
o
South
Korea
o
Japan
o
India
o
Australia
o
Singapore
·
North America
o
US
o
Canada
o
Mexico
·
Europe
o
Russia
o
Turkey
o
Switzerland
o
Spain
o
France
o
Germany
o
Italy
o
UK
·
South America
o
Brazil
o
Argentina
o
Rest
of South America
·
Middle East & Africa
o
South
Africa
o
Egypt
o
United
Arab Emirates
Key Developments in the Market:
· In
December 2017, Boehringer Ingelheim International GmbHannounced a collaborative
agreement on the discovery and development of orally available novel Locked
Nucleic Acid (LNA) oligonucleotides for the treatment of inflammatory bowel
diseases (IBDs) with Roche. Together, Boehringer Ingelheim and Roche will leverage
complementary expertise and innovative LNA technology to bring novel treatment
approaches to IBD patients.
·
In
February 2018, Regentys, a regenerative medicine company, announced its
partnership with Cook Biotech Inc., to develop a novel treatment for ulcerative
colitis. Under the terms, Cook Biotech will develop and manufacture Regentys’
licensed clinical product, ECMH Rectal Solution (Extracellular Matrix
Hydrogel), which will be used in first-in-man clinical studies conducted by
Regentys in 2018.
Inquiry Before
Buying @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-ulcerative-colitis-market
Competitive Analysis: Global Ulcerative Colitis Market
Global ulcerative colitis market is highly fragmented and the
major players have used various strategies such as new product launches,
expansions, agreements, joint ventures, partnerships, acquisitions, and others
to increase their footprints in this market. The report includes market shares
of ulcerative colitis market for Global, Europe, North America, Asia-Pacific,
South America and Middle East & Africa.
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric
Market research and consulting firm with unparalleled level of resilience and
integrated approaches. We are determined to unearth the best market
opportunities and foster efficient information for your business to thrive in
the market. Data Bridge Market Research provides appropriate solutions to the
complex business challenges and initiates an effortless decision-making
process.
Data
Bridge adepts in creating satisfied clients who reckon upon our services and
rely on our hard work with certitude. Get Customization and Discount on
Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 %
client satisfying rate.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Comments
Post a Comment